



Development of a *Leishmania* identification PCR assay for use with next generation PoC diagnostic devices

Dr Henry M. Staines

DoI : SK is on the Scientific Board of QuantuMDx and both HMS and SK are shareholders



Leishmaniasis

- 98 countries, 9th largest disease burden among infectious diseases
- VL Incidence 0.2 0.4 mil ~50,000 deaths, CL Incidence 0.7 to 1.2 mil
- Diagnosis Microscopy, Serology, Molecular but no simple, cheap, sensitive PoC assay



The Partners

- LSHTM Prof Simon Croft (PI), Dr Vanessa Yardley, Dr Evangelia Piperaki
- QuantuMDx industrial partner (SME based in Newcastle)
- SGUL Prof Sanjeev Krishna, Dr Henry Staines, Ms Rebekah Burrow, Dr David Clark



QuantuMDs





QuantuMDx Tech



The Project

- Use the platform PoC technologies that QuantuMDx have developed for diagnosis of *Leishmaniasis*
- Develop a sensitive PCR assay for diagnosis of *Leishmaniasis* that is compatible
 - Small sample volume (10-20 microL)
 - Leishmania donovani, multicopy target (kDNA)
- Demonstrate the assay with QuantuMDx's PoC device





Thank you to the Tropical Infectious Disease Consortium for this opportunity



Public Health England





